Ask AI
ProCE Banner Activity

Experts Discuss Key Questions in the Contemporary Management of Myelofibrosis

Clinical Thought

In this focused commentary, 3 experts answer questions posed at an ASCO 2024 symposium regarding the use of JAK inhibitors and emerging therapeutics in treating MF.

Released: July 23, 2024

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline

Faculty Disclosure

Primary Author

Prithviraj Bose, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, Cogent, CTI, Disc, Geron, GlaxoSmithKline, Incyte, Ionis, Jubilant, Karyopharm, Keros, Morphic, Morphosys, Novartis, Ono Pharma, Pharma Essentia, Raythera, Sumitomo; researcher: Ajax, Blueprint, Bristol Myers Squibb, Cogent, CTI, Disc, Geron, Incyte, Ionis, Janssen, Kartos, Karyopharm, Morphosys, Sumitomo, Telios.

Lucia Masarova, MD

Assistant Professor
Leukemia Department
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Lucia Masarova, MD: consultant/advisor/speaker: Cogent, GlaxoSmithKline, MorphoSys, PharmaEssentia.

Raajit K. Rampal, MD, PhD

Director
MPN and Rare Hematologic Disease Program
New York, New York

Raajit K. Rampal, MD, PhD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, Cogent, Constellation/Morphosys, CTI BioPharma/Sobi, Dainippon, Disc Medicine, Galecto, Incyte, Jazz, Kartos, Karyopharm, Novartis, OPNA, PharmaEssentia, Promedior, Sierra Oncology/GSK, Stemline, Sumitomo, Zentalis; researcher: Biomed Valley Discoveries, Constellation/Morphosys, Incyte, Ryvu, Stemline, Zentalis.